Logo image
Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States
Journal article   Open access   Peer reviewed

Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States

Henry H. Bernstein, Edward P. Rothstein, Pennridge Pediatric Associates, Michael E. Pichichero, John L. Green, Elmwood Pediatrics, Keith S. Reisinger, Mark M. Blatter, Judith Halpern, Allan M. Arbeter, …
Vaccine, v 13(17), pp 1631-1635
1995
PMID: 8719512
url
https://doi.org/10.1016/0264-410x(95)00137-pView
Published, Version of Record (VoR) Open
url
https://doi.org/10.1016/0264-410X(95)00137-PView
Published, Version of Record (VoR) Open

Abstract

Acellular pertussis vaccine immunization whole-cell pertussis vaccine
Five hundred and fifty-seven infants received either an acellular pertussis (DTaP) vaccine containing pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin (PRN) or one of two commercially available whole-cell pertussis (DTP) vaccines at 2, 4 and 6 months. One month after the third immunization, IgG antibody values to pertussis toxoid, filamentous hemagglutinin and PRN were significantly greater following DTaP than either DTP ( P<0.05). When reactions within 48 h after all three doses of vaccine were combined, fever 101°, ≥moderate fussiness, ≥moderate pain, swelling 10 mm, and erythema 10 mm occurred less often after DTaP compared with DTP-Connaught ( P<0.001). The same adverse events were also less after DTaP compared with DTP-Lederle ( P<0.05), except for erythema 10 mm. This three-component DTaP vaccine produced fewer adverse events and greater antibody values to PT, FHA and PRN in comparison with either licensed DTP vaccine when given as the primary series.; Acellular pertussis vaccine; whole-cell pertussis vaccine; immunization

Metrics

12 Record Views
24 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
Web of Science research areas
Immunology
Medicine, Research & Experimental
Logo image